Collierville Dialysis is a medicare approved dialysis facility center in Collierville, Tennessee and it has 15 dialysis stations. It is located in Shelby county at 791 West Poplar Avenue, Collierville, TN, 38017. You can reach out to the office of Collierville Dialysis at (901) 853-7809. This dialysis clinic is managed and/or owned by Davita. Collierville Dialysis has the following ownership type - Profit. It was first certified by medicare in May, 2002. The medicare id for this facility is 442648 and it accepts patients under medicare ESRD program.
| Name | Collierville Dialysis |
|---|---|
| Location | 791 West Poplar Avenue, Collierville, Tennessee |
| No. of Dialysis Stations | 15 |
| Medicare ID | 442648 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 791 West Poplar Avenue, Collierville, Tennessee, 38017 | |
| (901) 853-7809 | |
News Archive
A study led by the University of Southampton, funded by Cancer Research UK, has shown a new drug - originally developed to tackle the scarring of organ tissue - could help to significantly improve the success rate of cancer immunotherapy treatment.
Heart disease is a major global health problem-myocardial infarction annually affects more than one million people in the U.S. alone, and there is still no effective treatment.
A new comprehensive natural history study about Amish nemaline myopathy in the Old Order Amish population focuses on the promise of gene therapy for this lethal disorder.
Palatin Technologies, Inc. today announced that the last patient has completed treatment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD).
› Verified 2 days ago
| NPI Number | 1245292861 |
| Organization Name | Collierville Dialysis |
| Doing Business As | Total Renal Care Inc |
| Address | 791 W Poplar Ave Collierville, Tennessee, 38017 |
| Phone Number | (901) 853-7809 |
News Archive
A study led by the University of Southampton, funded by Cancer Research UK, has shown a new drug - originally developed to tackle the scarring of organ tissue - could help to significantly improve the success rate of cancer immunotherapy treatment.
Heart disease is a major global health problem-myocardial infarction annually affects more than one million people in the U.S. alone, and there is still no effective treatment.
A new comprehensive natural history study about Amish nemaline myopathy in the Old Order Amish population focuses on the promise of gene therapy for this lethal disorder.
Palatin Technologies, Inc. today announced that the last patient has completed treatment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD).
› Verified 2 days ago
| Dialysis patients with Hemoglobin data | 24 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 13 |
News Archive
A study led by the University of Southampton, funded by Cancer Research UK, has shown a new drug - originally developed to tackle the scarring of organ tissue - could help to significantly improve the success rate of cancer immunotherapy treatment.
Heart disease is a major global health problem-myocardial infarction annually affects more than one million people in the U.S. alone, and there is still no effective treatment.
A new comprehensive natural history study about Amish nemaline myopathy in the Old Order Amish population focuses on the promise of gene therapy for this lethal disorder.
Palatin Technologies, Inc. today announced that the last patient has completed treatment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD).
› Verified 2 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 39 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 322 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
A study led by the University of Southampton, funded by Cancer Research UK, has shown a new drug - originally developed to tackle the scarring of organ tissue - could help to significantly improve the success rate of cancer immunotherapy treatment.
Heart disease is a major global health problem-myocardial infarction annually affects more than one million people in the U.S. alone, and there is still no effective treatment.
A new comprehensive natural history study about Amish nemaline myopathy in the Old Order Amish population focuses on the promise of gene therapy for this lethal disorder.
Palatin Technologies, Inc. today announced that the last patient has completed treatment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD).
› Verified 2 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Collierville Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 41 |
| Hypercalcemia patient months | 346 |
| Patients with Serumphosphor | 47 |
| Patients with Serumphosphor less than 3.5 mg/dL | 15 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 27 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 31 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 15 |
| Patients with Serumphosphor greater than 7 mg/dL | 11 |
News Archive
A study led by the University of Southampton, funded by Cancer Research UK, has shown a new drug - originally developed to tackle the scarring of organ tissue - could help to significantly improve the success rate of cancer immunotherapy treatment.
Heart disease is a major global health problem-myocardial infarction annually affects more than one million people in the U.S. alone, and there is still no effective treatment.
A new comprehensive natural history study about Amish nemaline myopathy in the Old Order Amish population focuses on the promise of gene therapy for this lethal disorder.
Palatin Technologies, Inc. today announced that the last patient has completed treatment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD).
› Verified 2 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 40 |
| Patient months included in arterial venous fistula and catheter summaries | 294 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 69 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 7 |
News Archive
A study led by the University of Southampton, funded by Cancer Research UK, has shown a new drug - originally developed to tackle the scarring of organ tissue - could help to significantly improve the success rate of cancer immunotherapy treatment.
Heart disease is a major global health problem-myocardial infarction annually affects more than one million people in the U.S. alone, and there is still no effective treatment.
A new comprehensive natural history study about Amish nemaline myopathy in the Old Order Amish population focuses on the promise of gene therapy for this lethal disorder.
Palatin Technologies, Inc. today announced that the last patient has completed treatment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD).
› Verified 2 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 34 |
| Hospitalization Rate in facility | 154.7 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 328.6 |
| Hospitalization Rate: Lower Confidence Limit | 77.3 |
News Archive
A study led by the University of Southampton, funded by Cancer Research UK, has shown a new drug - originally developed to tackle the scarring of organ tissue - could help to significantly improve the success rate of cancer immunotherapy treatment.
Heart disease is a major global health problem-myocardial infarction annually affects more than one million people in the U.S. alone, and there is still no effective treatment.
A new comprehensive natural history study about Amish nemaline myopathy in the Old Order Amish population focuses on the promise of gene therapy for this lethal disorder.
Palatin Technologies, Inc. today announced that the last patient has completed treatment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD).
› Verified 2 days ago
The rate of readmission show you whether patients who were being treated regularly at Collierville Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 20.3 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 37.3 |
| Readmission Rate: Lower Confidence Limit | 8.3 |
News Archive
A study led by the University of Southampton, funded by Cancer Research UK, has shown a new drug - originally developed to tackle the scarring of organ tissue - could help to significantly improve the success rate of cancer immunotherapy treatment.
Heart disease is a major global health problem-myocardial infarction annually affects more than one million people in the U.S. alone, and there is still no effective treatment.
A new comprehensive natural history study about Amish nemaline myopathy in the Old Order Amish population focuses on the promise of gene therapy for this lethal disorder.
Palatin Technologies, Inc. today announced that the last patient has completed treatment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD).
› Verified 2 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Collierville Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.3 (As Expected) |
| SIR: Upper Confidence Limit | 3.53 |
| SIR: Lower Confidence Limit | .33 |
News Archive
A study led by the University of Southampton, funded by Cancer Research UK, has shown a new drug - originally developed to tackle the scarring of organ tissue - could help to significantly improve the success rate of cancer immunotherapy treatment.
Heart disease is a major global health problem-myocardial infarction annually affects more than one million people in the U.S. alone, and there is still no effective treatment.
A new comprehensive natural history study about Amish nemaline myopathy in the Old Order Amish population focuses on the promise of gene therapy for this lethal disorder.
Palatin Technologies, Inc. today announced that the last patient has completed treatment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD).
› Verified 2 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Collierville Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 27 |
| Transfusion Rate in facility | 25.9 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 151.8 |
| Transfusion Rate: Lower Confidence Limit | 5.5 |
News Archive
A study led by the University of Southampton, funded by Cancer Research UK, has shown a new drug - originally developed to tackle the scarring of organ tissue - could help to significantly improve the success rate of cancer immunotherapy treatment.
Heart disease is a major global health problem-myocardial infarction annually affects more than one million people in the U.S. alone, and there is still no effective treatment.
A new comprehensive natural history study about Amish nemaline myopathy in the Old Order Amish population focuses on the promise of gene therapy for this lethal disorder.
Palatin Technologies, Inc. today announced that the last patient has completed treatment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD).
› Verified 2 days ago
The rate of mortality show you whether patients who were being treated regularly at Collierville Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 165 |
| Mortality Rate in facility | 19.4 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 29.1 |
| Mortality Rate: Lower Confidence Limit | 12.3 |
News Archive
A study led by the University of Southampton, funded by Cancer Research UK, has shown a new drug - originally developed to tackle the scarring of organ tissue - could help to significantly improve the success rate of cancer immunotherapy treatment.
Heart disease is a major global health problem-myocardial infarction annually affects more than one million people in the U.S. alone, and there is still no effective treatment.
A new comprehensive natural history study about Amish nemaline myopathy in the Old Order Amish population focuses on the promise of gene therapy for this lethal disorder.
Palatin Technologies, Inc. today announced that the last patient has completed treatment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD).
› Verified 2 days ago
Collierville Dialysis Location: 791 West Poplar Avenue, Collierville, Tennessee, 38017 Phone: (901) 853-7809 |
News Archive
A study led by the University of Southampton, funded by Cancer Research UK, has shown a new drug - originally developed to tackle the scarring of organ tissue - could help to significantly improve the success rate of cancer immunotherapy treatment.
Heart disease is a major global health problem-myocardial infarction annually affects more than one million people in the U.S. alone, and there is still no effective treatment.
A new comprehensive natural history study about Amish nemaline myopathy in the Old Order Amish population focuses on the promise of gene therapy for this lethal disorder.
Palatin Technologies, Inc. today announced that the last patient has completed treatment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD).
› Verified 2 days ago